Although Ro 31–8220 was previously identified as a PKC inhibitor, the authors demonstrate that the compound’s impact on DM1 pathomechanism is independent of PKC, suggesting involvement of other kinases or even a non-kinase role. This evidence concerns the gene PRRT2 and myotonic dystrophy type 1.